share_log

榮昌生物:海外監管公告 - 關於本次募集資金投向屬於科技創新領域的說明

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:24
Summary by Moomoo AI
荣昌生物宣布,將於2024年向特定對象發行A股股票,募集資金總額不超過255億元人民幣,用於投資新藥研發項目。該公司專注於創新型生物製藥,擁有多個核心技術平台和一系列候選生物藥產品。募集資金將用於加快在研產品的臨床試驗和上市註冊進程,並推動公司在肿瘤、自身免疫性疾病及眼科領域的研發能力。荣昌生物的募資計劃符合國家產業政策,旨在提升公司的科技創新水平和產品競爭力,並促進可持續發展。本次募資項目已於2024年3月29日公布,並由公司及其全資子公司上海荣昌生物科技有限公司作為實施主體。
荣昌生物宣布,將於2024年向特定對象發行A股股票,募集資金總額不超過255億元人民幣,用於投資新藥研發項目。該公司專注於創新型生物製藥,擁有多個核心技術平台和一系列候選生物藥產品。募集資金將用於加快在研產品的臨床試驗和上市註冊進程,並推動公司在肿瘤、自身免疫性疾病及眼科領域的研發能力。荣昌生物的募資計劃符合國家產業政策,旨在提升公司的科技創新水平和產品競爭力,並促進可持續發展。本次募資項目已於2024年3月29日公布,並由公司及其全資子公司上海荣昌生物科技有限公司作為實施主體。
Rong Cheong Bios announced that it will issue A shares to select entities in 2024, with a total of no more than RMB 255 billion to invest in new drug R&D projects. The company focuses on innovative biopharmaceuticals with multiple core technology platforms and a range of candidate biopharmaceutical products. The funds raised will be used to accelerate clinical trials and market registrations of investigational products and boost the company's R&D capabilities in the fields of oncology, autoimmune diseases and ophthalmology. RONG CHANG BIO'S FUNDRAISING PROGRAM IS IN LINE WITH THE NATIONAL INDUSTRY POLICY AND AIMS TO ENHANCE THE COMPANY'S LEVEL OF TECHNOLOGY INNOVATION AND PRODUCT COMPETITIVENESS, AND PROMOTE SUSTAINABILITY. The crowdfunding project was announced on 29 March 2024 and implemented by the Company and its wholly-owned subsidiary Shanghai Rongchang Biotechnology Co., Ltd.
Rong Cheong Bios announced that it will issue A shares to select entities in 2024, with a total of no more than RMB 255 billion to invest in new drug R&D projects. The company focuses on innovative biopharmaceuticals with multiple core technology platforms and a range of candidate biopharmaceutical products. The funds raised will be used to accelerate clinical trials and market registrations of investigational products and boost the company's R&D capabilities in the fields of oncology, autoimmune diseases and ophthalmology. RONG CHANG BIO'S FUNDRAISING PROGRAM IS IN LINE WITH THE NATIONAL INDUSTRY POLICY AND AIMS TO ENHANCE THE COMPANY'S LEVEL OF TECHNOLOGY INNOVATION AND PRODUCT COMPETITIVENESS, AND PROMOTE SUSTAINABILITY. The crowdfunding project was announced on 29 March 2024 and implemented by the Company and its wholly-owned subsidiary Shanghai Rongchang Biotechnology Co., Ltd.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more